NCT07181473招募中1 期
A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma7 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2025年8月25日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 7
- 主要终点
- Number of participants with Dose-limiting toxicities
研究概览
简要总结
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
The main objectives of this study are :
- To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101
- to show preliminary antitumor activity in patients with advanced solid tumors
Participants will:
- Receive intravenous (IV) infusions of TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose.
- Undergo regular tumor imaging to assess response.
- Provide blood samples for pharmacokinetics (PK) and biomarker analysis.
- Be monitored for side effects and overall tolerability.
This study is being conducted in adult patients with advanced or metastatic solid tumors who have exhausted standard treatment options
详细描述
This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary efficacy of TJ101, a bispecific antibody-drug conjugate (ADC) targeting EGFR and B7-H3, in patients with advanced or metastatic solid tumors.
Study Objectives Phase Ia (Dose Escalation)
- Primary: Assess safety/tolerability; determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended dose(s) for expansion (RDEs).
- Secondary: Characterize PK profile, assess preliminary anti-tumor activity, and evaluate immunogenicity.
Phase Ib (Dose Expansion)
- Primary: Further assess safety and preliminary anti-tumor activity of TJ101 at the selected RDEs.
- Secondary: Further characterize PK profile and immunogenicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological and/or cytological diagnosis of advanced/metastatic solid tumors, who have failed standard treatment, or have no standard therapy.
- •Have at least one measurable lesion by RECIST v1.1 (Eisenhauer et al., 2009) for solid tumors.
- •Men or women ≥18 years old.
- •Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) of 0 to
- •Life expectancy of ≥ 12 weeks;
- •Patients with adequate organ function and the laboratory test criteria specifically defined as follows within 7 days prior to the first dosing.
- •Hepatic function: AST and ALT ≤ 2.5 x upper limit of normal (ULN); if liver metastases, then ≤ 5 x ULN. Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome.
- •Albumin ≥3g/dL.
- •Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN; APTT≤1.5×ULN.
- •Renal function: Creatinine clearance ≥ 60 mL/min (calculated by Cockcroft and Gault equation) (Cockcroft DW, 1976)
- •Hematopoietic function (without infusion of blood product, use of G-CSF or other treatments to correct blood count within 14 days): Hemoglobin (HGB) ≥ 90 g/L; Platelet count (PLT) ≥ 100×109/L; Absolute neutrophil count (ANC) ≥ 1.5×109/L;
- •Serum pregnancy test (for female of childbearing potential) negative within 7 days prior to first dosing of study treatment. Male and female patients of childbearing potential must agree to use effective methods of contraception from the time of informed consent, throughout the study and for 6 months after the last dose of the investigational product.
- •Willing to participate in the clinical trial, understand and sign the informed consent, and comply with the study visits and procedures.
排除标准
- •Has received treatment of topoisomerase 1 inhibitors (TOP1i), including topotecan, irinotecan, belotecan, and TOP1i-based antibody-drug conjugates (ADCs, eg, sacituzumab govitecan, trastuzumab deruxtecan, zalontamab brengitecan, sacituzumab tirumotecan etal);
- •Has known hypersensitivity to any component of TJ101 or has a history of severe hypersensitivity reactions to other monoclonal antibodies;
- •Has received mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral fluorouracil-like drugs such as S-1, capecitabine, or palliative radiotherapy within 2 weeks prior to the first administration; Has received other chemotherapy, biological therapy, immunotherapy, major surgery, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase) and other anti-tumor therapy within 5 half-lives or 28 days, whichever is shorter, prior to the first administration of TJ101; Has received anti-tumor herbal medicine within 14 days prior to first dose of TJ101;
- •Has received a strong or moderate CYP3A4 inhibitor within 3 half-lives;
- •Received an investigational drug within 28 days or 2 half-lives (whichever is shorter) prior to first dose of TJ101; Current participation in other interventional clinical studies (participation in survival follow-up is allowed);
- •Toxic effects of prior anti-tumor therapy have not recovered to NCI-CTCAE V5.0 Grade ≤1 (excluding alopecia and skin pigmentation). Subject with irreversible toxicities caused by prior anti-tumor therapy (eg, hearing loss) that will not increase the safety risk may be eligible at the discretion of the Investigator.
- •Has a history of (non-infectious) interstitial lung disease (ILD) that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis can't be ruled out by imaging at screening.
- •Presence of severe dry eye syndrome, severe keratitis, severe conjunctivitis, or other severe conditions that may increase the risk of corneal epithelial damage at the discretion of investigator.
- •Uncontrolled or significant cardiovascular disease, including:
- •Prolongation of the average Corrected QT interval (QTc, Fridericia's correction formula used) (> 470 ms regardless of sex).
- •Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (class II-IV of New York Heart Association [NYHA]) or acute myocardial infarction within preceding 6 months.
- •History of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
- •Uncontrolled hypertension defined as systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg while receiving more than one kind of antihypertensive drug.
- •For patients with documented positive virology status of hepatitis, as confirmed by Screening hepatitis B virus (HBV) and hepatitis C virus (HCV) tests, only the following patients may be eligible as evaluated by the sponsor and investigator:
- •Patients with active hepatitis B: HBV DNA ≤500 IU/mL during Screening. Patients who are hepatitis C virus antibody positive (HCV Ab+), who have controlled infection (HCV RNA≤ULN by polymerase chain reaction [PCR] either spontaneously or in response to a successful prior course of anti-HCV therapy at Screening). Patients with controlled infections must undergo periodic monitoring of HCV RNA as per treating physician.
- •Known HIV infection;
- •Severe infection, including but not limited to hospitalization due to infection, bacteraemia, or severe pneumonia complications, occurs within 4 weeks prior to initiation of study treatment; Or patients who received therapeutic oral or intravenous antibiotics within two weeks prior to starting study treatment, and who received prophylactic antibiotics (e.g., for the prevention of urinary tract infection or chronic obstructive pulmonary disease);
- •Active central nervous system (CNS) metastases or meningeal metastases. Subjects may be enrolled in the study if their CNS metastases have received adequate local therapy and have been clinical stable for at least 4 weeks (ie, imaging shows no progression of the brain lesion and neurologically relevant symptoms are stable), and require a dose of prednisone of ≤20 mg/day (or equivalent dose).
- •Other malignancies within 3 years prior to initiation of TJ101 treatment (other than non-melanoma basal cell carcinoma or squamous cell carcinoma of the skin, breast/cervical carcinoma in situ, superficial bladder carcinoma that have received radical treatment and no evidence of disease recurrence) will confound safety/efficacy of this trial or pose a risk to the participants;
- •Female patients who are lactating or breastfeeding.
- •The investigator believes that the subject may have other factors that may affect the results of the study and interfere with the subject's participation in the entire study process, including previous or existing physical conditions, abnormal treatment or laboratory tests, and the subject's unwillingness to comply with all procedures, restrictions, and requirements of the study.
研究组 & 干预措施
TJ101
Experimental
TJ101 will be infused intravenously once every 3 weeks. Participants will receive TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose.
干预措施: TJ101 (Drug)
结局指标
主要结局
Number of participants with Dose-limiting toxicities
时间窗: 21 Days
Measuring the number of patients with Dose-limiting toxicities (DLTs). A DLT is defined as any of the following events that are not clearly due to the underlying disease or extraneous causes: Hematological toxicities: Grade 4 neutrophil count decreased lasting \>7 days; Grade ≥3 febrile neutropenia; Grade ≥3 platelet count decreased with clinically significant hemorrhage; Grade 4 anaemia; Non-Hematological toxicities: Death; Hy's law cases; Grade ≥3 non-hematological toxicities.
Number of participants with Serious Adverse Events (SAEs)
时间窗: 2 years
Measuring the number of patients with Serious Adverse Events (SAEs)
Number of participants with treatment-emergent adverse events (TEAEs)
时间窗: 2 years
Measuring the number of patients with AEs that occur after first study dose till 30 days after the last dose
Number of participants with treatment-related adverse events (TRAEs)
时间窗: 2 years
Measuring the number of patients with treatment-related TEAEs
次要结局
- Objective response rate (ORR)(2 years)
- Disease control rate (DCR)(2 years)
- Duration of response (DoR)(2 years)
- Progression-free survival (PFS)(2 years)
- Overall survival (OS)(2 years)
- Maximum observed concentration (Cmax)(1 year)
- Time to Cmax (Tmax)(1 year)
- Area under the concentration versus time curve (AUC)(1 year)
- half-life time (t1/2)(1 year)
- Clearance (CL)(1 year)
- Volume of distribution(1 year)
- Elimination rate constant (λz)(1 year)
- Mean residence time (MRT)(1 year)
- Proportion of participants with neutralizing antibodies (NAb)(1 year)
- Proportion of participants with anti-drug antibodies (ADA)(1 year)
- Titer of anti-drug antibodies (ADA)(1 year)
研究者
研究点 (7)
Loading locations...
相似试验
尚未招募
不适用
A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing LossDeafnessNCT07012746Yilai Shu60
进行中（未招募）
1 期
Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy AdultsNCT06943378Just-Evotec Biologics104
已完成
1 期
A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionSubjects With Renal ImpairmentHealthy SubjectsNCT05895812Shanghai Vinnerna Biosciences Co., Ltd.24
招募中
2 期
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic CancerPancreas CancerNCT05638698University of Kansas Medical Center24
已完成
3 期
JT001 (VV116) for the Treatment of COVID-19Mild to Moderate COVID-19NCT05582629Shanghai Vinnerna Biosciences Co., Ltd.1,369